HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Buhl, E. S. Articles by Lund, S. Search for Related Content PubMed PubMed Citation Articles by Buhl, E. S. Articles by Lund, S. Social Bookmarking                What's this?

Long-Term AICAR Administration Reduces Metabolic Disturbances and Lowers Blood Pressure in Rats Displaying Features of the Insulin Resistance Syndrome

¹ Medical Research Laboratory and Medical Department M (Endocrinology and Diabetes), Aarhus University Hospital, Aarhus Kommunehospital, Aarhus, Denmark
² Research Laboratory for Biochemical Pathology, Institute for Experimental Clinical Research, University of Aarhus, Aarhus Kommunehospital, Aarhus, Denmark
³ Department of Endocrinology and Metabolism C, Aarhus University Hospital, Aarhus Amtssygehus, Aarhus, Denmark
⁴ Steno Diabetes Centre and Hagedorn Research Institute, Gentofte, Copenhagen, Denmark
⁵ Institute of Clinical Pharmacology, University of Aarhus, Aarhus, Denmark

The insulin resistance syndrome is characterized by several risk factors for cardiovascular disease. Chronic chemical activation of AMP-activated protein kinase by the adenosine analog 5-aminoimidazole-4-carboxamide-1-ß -D-ribofuranoside (AICAR) has been shown to augment insulin action, upregulate mitochondrial enzymes in skeletal muscles, and decrease the content of intra-abdominal fat. Furthermore, acute AICAR exposure has been found to reduce sterol and fatty acid synthesis in rat hepatocytes incubated in vitro as well as suppress endogenous glucose production in rats under euglycemic clamp conditions. To investigate whether chronic AICAR administration, in addition to the beneficial effects on insulin sensitivity, is capable of improving other phenotypes associated with the insulin resistance syndrome, obese Zucker (fa/fa) rats (n = 6) exhibiting insulin resistance, hyperlipidemia, and hypertension were subcutaneously injected with AICAR (0.5 mg/g body wt) daily for 7 weeks. Obese control rats were either pair-fed (PF) (n = 6) or ad libitum-fed (AL) (n = 6). Lean Zucker rats (fa/-) (n = 8) served as a reference group. AICAR administration significantly reduced plasma triglyceride levels (P < 0.01 for AICAR vs. AL, and P = 0.05 for AICAR vs. PF) and free fatty acids (P < 0.01 for AICAR vs. AL, and P < 0.05 for AICAR vs. PF) and increased HDL cholesterol levels (P < 0.01 for AICAR vs. AL and PF). AICAR treatment also lowered systolic blood pressure by 14.6 ± 4.3 mmHg (P < 0.05), and AICAR-treated animals exhibited a tendency toward decreased intra-abdominal fat content. Furthermore, AICAR administration normalized the oral glucose tolerance test and decreased fasting concentrations of glucose and insulin close to the level of the lean animals. Finally, in line with previous findings, AICAR treatment was also found to enhance GLUT4 protein expression and to increase maximally insulin-stimulated glucose transport in primarily white fast-twitch muscles. Our data provide strong evidence that long-term administration of AICAR improves glucose tolerance, improves the lipid profile, and reduces systolic blood pressure in an insulin-resistant animal model. The present study gives additional support to the hypothesis that AMPK activation might be a potential future pharmacological strategy for treating the insulin resistance syndrome.

CiteULike

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				O. Goransson, A. McBride, S. A. Hawley, F. A. Ross, N. Shpiro, M. Foretz, B. Viollet, D. G. Hardie, and K. Sakamoto Mechanism of Action of A-769662, a Valuable Tool for Activation of AMP-activated Protein Kinase J. Biol. Chem., November 9, 2007; 282(45): 32549 - 32560. [Abstract] [Full Text] [PDF]

				C. T. Putman, K. J. B. Martins, M. E. Gallo, G. D. Lopaschuk, J. A. Pearcey, I. M. MacLean, R. J. Saranchuk, and D. Pette {alpha}-Catalytic subunits of 5'AMP-activated protein kinase display fiber-specific expression and are upregulated by chronic low-frequency stimulation in rat muscle Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2007; 293(3): R1325 - R1334. [Abstract] [Full Text] [PDF]

				K. S.C. Rockl, M. F. Hirshman, J. Brandauer, N. Fujii, L. A. Witters, and L. J. Goodyear Skeletal Muscle Adaptation to Exercise Training: AMP-Activated Protein Kinase Mediates Muscle Fiber Type Shift Diabetes, August 1, 2007; 56(8): 2062 - 2069. [Abstract] [Full Text] [PDF]

				F. Goirand, M. Solar, Y. Athea, B. Viollet, P. Mateo, D. Fortin, J. Leclerc, J. Hoerter, R. Ventura-Clapier, and A. Garnier Activation of AMP kinase {alpha}1 subunit induces aortic vasorelaxation in mice J. Physiol., June 15, 2007; 581(3): 1163 - 1171. [Abstract] [Full Text] [PDF]

				M. C. Towler and D. G. Hardie AMP-Activated Protein Kinase in Metabolic Control and Insulin Signaling Circ. Res., February 16, 2007; 100(3): 328 - 341. [Abstract] [Full Text] [PDF]

				N. Fujii, N. Jessen, and L. J. Goodyear AMP-activated protein kinase and the regulation of glucose transport Am J Physiol Endocrinol Metab, November 1, 2006; 291(5): E867 - E877. [Abstract] [Full Text] [PDF]

				M. J. Yoon, G. Y. Lee, J.-J. Chung, Y. H. Ahn, S. H. Hong, and J. B. Kim Adiponectin Increases Fatty Acid Oxidation in Skeletal Muscle Cells by Sequential Activation of AMP-Activated Protein Kinase, p38 Mitogen-Activated Protein Kinase, and Peroxisome Proliferator-Activated Receptor {alpha} Diabetes, September 1, 2006; 55(9): 2562 - 2570. [Abstract] [Full Text] [PDF]

				E. W. Kraegen, A. K. Saha, E. Preston, D. Wilks, A. J. Hoy, G. J. Cooney, and N. B. Ruderman Increased malonyl-CoA and diacylglycerol content and reduced AMPK activity accompany insulin resistance induced by glucose infusion in muscle and liver of rats Am J Physiol Endocrinol Metab, March 1, 2006; 290(3): E471 - E479. [Abstract] [Full Text] [PDF]

				H. Sakoda, M. Fujishiro, J. Fujio, N. Shojima, T. Ogihara, A. Kushiyama, Y. Fukushima, M. Anai, H. Ono, M. Kikuchi, et al. Glycogen debranching enzyme association with {beta}-subunit regulates AMP-activated protein kinase activity Am J Physiol Endocrinol Metab, September 1, 2005; 289(3): E474 - E481. [Abstract] [Full Text] [PDF]

				T. Tanaka, S. Hidaka, H. Masuzaki, S. Yasue, Y. Minokoshi, K. Ebihara, H. Chusho, Y. Ogawa, T. Toyoda, K. Sato, et al. Skeletal Muscle AMP-Activated Protein Kinase Phosphorylation Parallels Metabolic Phenotype in Leptin Transgenic Mice Under Dietary Modification Diabetes, August 1, 2005; 54(8): 2365 - 2374. [Abstract] [Full Text] [PDF]

				E. B. Taylor, W. J. Ellingson, J. D. Lamb, D. G. Chesser, and W. W. Winder Long-chain acyl-CoA esters inhibit phosphorylation of AMP-activated protein kinase at threonine-172 by LKB1/STRAD/MO25 Am J Physiol Endocrinol Metab, June 1, 2005; 288(6): E1055 - E1061. [Abstract] [Full Text] [PDF]

				M. Foretz, N. Ancellin, F. Andreelli, Y. Saintillan, P. Grondin, A. Kahn, B. Thorens, S. Vaulont, and B. Viollet Short-Term Overexpression of a Constitutively Active Form of AMP-Activated Protein Kinase in the Liver Leads to Mild Hypoglycemia and Fatty Liver Diabetes, May 1, 2005; 54(5): 1331 - 1339. [Abstract] [Full Text] [PDF]

				R. Pold, L. S. Jensen, N. Jessen, E. S. Buhl, O. Schmitz, A. Flyvbjerg, N. Fujii, L. J. Goodyear, C. F. Gotfredsen, C. L. Brand, et al. Long-Term AICAR Administration and Exercise Prevents Diabetes in ZDF Rats Diabetes, April 1, 2005; 54(4): 928 - 934. [Abstract] [Full Text] [PDF]

				J. V. Swinnen, A. Beckers, K. Brusselmans, S. Organe, J. Segers, L. Timmermans, F. Vanderhoydonc, L. Deboel, R. Derua, E. Waelkens, et al. Mimicry of a Cellular Low Energy Status Blocks Tumor Cell Anabolism and Suppresses the Malignant Phenotype Cancer Res., March 15, 2005; 65(6): 2441 - 2448. [Abstract] [Full Text] [PDF]

				R. R. Pencek, J. Shearer, R. C. Camacho, F. D. James, D. B. Lacy, P. T. Fueger, E. P. Donahue, W. Snead, and D. H. Wasserman 5-Aminoimidazole-4-Carboxamide-1-{beta}-D-Ribofuranoside Causes Acute Hepatic Insulin Resistance In Vivo Diabetes, February 1, 2005; 54(2): 355 - 360. [Abstract] [Full Text] [PDF]

				J. D. Mulligan, A. A. Gonzalez, R. Kumar, A. J. Davis, and K. W. Saupe Aging Elevates Basal Adenosine Monophosphate-Activated Protein Kinase (AMPK) Activity and Eliminates Hypoxic Activation of AMPK in Mouse Liver J. Gerontol. A Biol. Sci. Med. Sci., January 1, 2005; 60(1): 21 - 27. [Abstract] [Full Text] [PDF]

				M. Zang, A. Zuccollo, X. Hou, D. Nagata, K. Walsh, H. Herscovitz, P. Brecher, N. B. Ruderman, and R. A. Cohen AMP-activated Protein Kinase Is Required for the Lipid-lowering Effect of Metformin in Insulin-resistant Human HepG2 Cells J. Biol. Chem., November 12, 2004; 279(46): 47898 - 47905. [Abstract] [Full Text] [PDF]

				M.-H. Zou, S. S. Kirkpatrick, B. J. Davis, J. S. Nelson, W. G. Wiles IV, U. Schlattner, D. Neumann, M. Brownlee, M. B. Freeman, and M. H. Goldman Activation of the AMP-activated Protein Kinase by the Anti-diabetic Drug Metformin in Vivo: ROLE OF MITOCHONDRIAL REACTIVE NITROGEN SPECIES J. Biol. Chem., October 15, 2004; 279(42): 43940 - 43951. [Abstract] [Full Text] [PDF]

				G. R. Steinberg, A. C. Smith, B. J. W. van Denderen, Z. Chen, S. Murthy, D. J. Campbell, G. J. F. Heigenhauser, D. J. Dyck, and B. E. Kemp AMP-Activated Protein Kinase Is Not Down-Regulated in Human Skeletal Muscle of Obese Females J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4575 - 4580. [Abstract] [Full Text] [PDF]

				J. A. Villena, B. Viollet, F. Andreelli, A. Kahn, S. Vaulont, and H. S. Sul Induced Adiposity and Adipocyte Hypertrophy in Mice Lacking the AMP-Activated Protein Kinase-{alpha}2 Subunit Diabetes, September 1, 2004; 53(9): 2242 - 2249. [Abstract] [Full Text] [PDF]

				S. L.M. Coort, D. M. Hasselbaink, D. P.Y. Koonen, J. Willems, W. A. Coumans, A. Chabowski, G. J. van der Vusse, A. Bonen, J. F.C. Glatz, and J. J.F.P. Luiken Enhanced Sarcolemmal FAT/CD36 Content and Triacylglycerol Storage in Cardiac Myocytes From Obese Zucker Rats Diabetes, July 1, 2004; 53(7): 1655 - 1663. [Abstract] [Full Text] [PDF]

				B. Brunmair, K. Staniek, F. Gras, N. Scharf, A. Althaym, R. Clara, M. Roden, E. Gnaiger, H. Nohl, W. Waldhausl, et al. Thiazolidinediones, Like Metformin, Inhibit Respiratory Complex I: A Common Mechanism Contributing to Their Antidiabetic Actions? Diabetes, April 1, 2004; 53(4): 1052 - 1059. [Abstract] [Full Text] [PDF]

				K. Hojlund, K. J. Mustard, P. Staehr, D. G. Hardie, H. Beck-Nielsen, E. A. Richter, and J. F. P. Wojtaszewski AMPK activity and isoform protein expression are similar in muscle of obese subjects with and without type 2 diabetes Am J Physiol Endocrinol Metab, February 1, 2004; 286(2): E239 - E244. [Abstract] [Full Text] [PDF]

				S. B. Jorgensen, B. Viollet, F. Andreelli, C. Frosig, J. B. Birk, P. Schjerling, S. Vaulont, E. A. Richter, and J. F. P. Wojtaszewski Knockout of the {alpha}2 but Not {alpha}1 5'-AMP-activated Protein Kinase Isoform Abolishes 5-Aminoimidazole-4-carboxamide-1-{beta}-4-ribofuranosidebut Not Contraction-induced Glucose Uptake in Skeletal Muscle J. Biol. Chem., January 9, 2004; 279(2): 1070 - 1079. [Abstract] [Full Text] [PDF]

				D. G. Hardie Minireview: The AMP-Activated Protein Kinase Cascade: The Key Sensor of Cellular Energy Status Endocrinology, December 1, 2003; 144(12): 5179 - 5183. [Abstract] [Full Text] [PDF]

				N. B. Ruderman, A. K. Saha, and E. W. Kraegen Minireview: Malonyl CoA, AMP-Activated Protein Kinase, and Adiposity Endocrinology, December 1, 2003; 144(12): 5166 - 5171. [Abstract] [Full Text] [PDF]

				M. Suwa, H. Nakano, and S. Kumagai Effects of chronic AICAR treatment on fiber composition, enzyme activity, UCP3, and PGC-1 in rat muscles J Appl Physiol, September 1, 2003; 95(3): 960 - 968. [Abstract] [Full Text] [PDF]

				S. L. McGee, K. F. Howlett, R. L. Starkie, D. Cameron-Smith, B. E. Kemp, and M. Hargreaves Exercise Increases Nuclear AMPK {alpha}2 in Human Skeletal Muscle Diabetes, April 1, 2003; 52(4): 926 - 928. [Abstract] [Full Text] [PDF]